Market Overview

UPDATE: Bank of America Initiates Neutral, $29 PO on The Medicines Company; Pipeline Uncertain

Related MDCO
The Medicines Company Announces BARDA Exercises Next Option on Contract for Support of the Development of CARBAVANCE® (meropenem/RPX7009) for Drug-Resistant Gram-Negative Pathogens
Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement Of Positive ALN-PCSsc Study Results
Top 2 Trade Alert Ideas October 7: Spark's Pullback, Synta Catalyst, M&A Activity (Seeking Alpha)

Bank of America initiated its coverage on The Medicines Company (NASDAQ: MDCO) with a Neutral rating and a price target of $29.

Bank of America noted, "MDCO is a profitable company focused on hospital-based drugs, with its key product Angiomax, the dominant anti-coagulant used in US angioplasty procedures (PCI). Our NPV estimate for Angiomax with assumed generic entry in 2019 is $24/sh, with another $4.50 for net cash. We attribute minimal risk-adjusted value for MDCO's late-stage pipeline products due to upcoming binary phase 3 results near year-end that in our view represent meaningful upside and downside drivers to the stock. If near-term phase 3 results are unfavorable, we would expect MDCO to pursue bolt-on acquisitions of hospital-based products."

The Medicines Company closed at $25.08 on Tuesday.

Latest Ratings for MDCO

Aug 2015RBC CapitalMaintainsOutperform
Aug 2015JefferiesMaintainsBuy
Aug 2015JefferiesUpgradesHoldBuy

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (MDCO)

Get Benzinga's Newsletters